Polyrizon Ltd. filed its interim condensed financial statements and management discussion for the six months ended June 30, 2026. The company reported a net loss of $1.4 million, with cash and cash equivalents increasing to $8.4 million from proceeds of a $3.5 million registered direct offering closed on April 8, 2026. Subsequent to the balance sheet date, Polyrizon exercised warrants for Quantum X Labs Inc. shares on July 2, 2026, and closed another registered direct offering with gross proceeds of approximately $4.0 million on September 4, 2026. The company also announced a reverse share split effective November 28, 2025, at a ratio of one-for-6. Polyrizon Ltd. is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment against viruses and allergens.
